Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimen

Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia

Bone Marrow Transplantation volume 33, pages 471–476 (2004)Cite this article

Summary:

Autologous peripheral blood stem cell transplantation (APBSCT) after intensifying conditioning is one of the post-remission therapeutic options in childhood acute myeloid leukemia (AML) patients without a matched family donor, but the optimal conditioning regimen has not been defined. This study was performed to evaluate the efficacy of a novel conditioning regimen without busulfan or total body irradiation. In total, 28 children with AML underwent APBSCT with BCVAC (BCNU, etoposide, cytosine arabinoside and cyclophosphamide) conditioning regimen during first remission. The event-free survival rate was 71.43% for all patients and the only cause of treatment failure was relapse. Eight male patients recurred at 1–11 months (median 5 months) after APBSCT. One patient remains alive with salvage therapy after relapse. With the exception of fever, mucositis and diarrhea, no serious complications occurred during APBSCT, including veno-occlusive disease (VOD), and there was no transplantation-related mortality. One patient developed secondary MDS after APBSCT but recovered hematologically on medication. APBSCT with BCVAC conditioning was found to be a safe and effective alternative option for patients with childhood AML in first remission, without a matched family donor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Rowe JM, Tallman MS . Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood 1997; 91: 2121–2126.

    Google Scholar 

  2. Wood WG, Neudoef S, Gold S et al. Children's Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001; 97: 56–62.

    Article  Google Scholar 

  3. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428–1434.

    Article  CAS  Google Scholar 

  4. Amadori S, Testi AM, Arico M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11: 1046–1054.

    Article  CAS  Google Scholar 

  5. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997; 20: 821–826.

    Article  CAS  Google Scholar 

  6. Martin C, Torres A, Leon A et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Bone Marrow Transplant 1998; 21: 375–382.

    Article  CAS  Google Scholar 

  7. Gorin NC . Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073–1090.

    CAS  Google Scholar 

  8. Locatelli F, Labopin M, Ortega J et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003; 101: 1611–1619.

    Article  CAS  Google Scholar 

  9. Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130–140.

    Article  CAS  Google Scholar 

  10. Matsuyama T, Horibe K, Kato K, Kojima SS . Bone marrow transplantation for children with acute myelogenous leukaemia in the first complete remission. Eur J Cancer 2000; 36: 368–375.

    Article  CAS  Google Scholar 

  11. Mehta J, Powles R, Singhal S, Treleaven J . Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995; 15: 652–653.

    CAS  Google Scholar 

  12. Motta MR, Mangianti S, Rizzi S et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Exp Hematol 1997; 25: 1261–1269.

    CAS  Google Scholar 

  13. Takaue Y, Watanabe T, Hoshi Y et al. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer 1991; 67: 1830–1837.

    Article  CAS  Google Scholar 

  14. Takaue Y, Watanabe A, Murakami T et al. High-dose chemotherapy and blood stem cell autografts for children with first relapsed acute lymphoblastic leukemia: a pilot study of the Children's Cancer and Leukemia Study Group of Japan (CCLSG). Med Pediatr Oncol 1994; 23: 20–25.

    Article  CAS  Google Scholar 

  15. Vignetti M, Rondelli R, Locatelli F et al. Autologous bone marrow transplantation in children with acute myeloblastic leukemia: report from the Italian National Pediatric Registry (AIEOP-BMT). Bone Marrow Transplant 1996; 18 (Suppl 2): 59–62.

    PubMed  Google Scholar 

  16. Meloni G, De Fabritiis P, Petti MC, Mandelli F . BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282–2285.

    CAS  Google Scholar 

  17. Sievers EL, Lange BJ, Sondel PM et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914–919.

    Article  CAS  Google Scholar 

  18. Sievers EL, Lange BJ, Sondel PM et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6 (Suppl 1): S39–S44.

    PubMed  Google Scholar 

  19. Sanders JE . Stem-cell transplant preparative regimens. Pediatr Transplant 1999; 3 (Suppl 1): 23–34.

    Article  Google Scholar 

  20. Sevilla J, Rodriguez A, Hernandez-Maraver D et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002; 81: 11–15.

    Article  CAS  Google Scholar 

  21. Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.

    CAS  Google Scholar 

  22. Ebb DH, Weinstein HJ . Diagnosis and treatment of childhood acute myelogenous leukemia. Pediatr Clin N Am 1997; 44: 847–862.

    Article  CAS  Google Scholar 

  23. Wells RJ, Woods WG, Buckley JD et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol 1994; 12: 2367–2377.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was partially supported by grant from the Seoul National University College of Medicine, Research Fund 2002 for Pediatrics.

Author information

Authors and Affiliations

  1. Pediatric Oncology Branch, National Cancer Center, Gyeonggi-do, Republic of Korea

    H J Kang

  2. Division of Hematology/Oncology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea

    H Y Shin, H S Choi & H S Ahn

  3. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    K S Han

Authors
  1. H J Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Y Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H S Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K S Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H S Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H S Ahn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, H., Shin, H., Choi, H. et al. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia. Bone Marrow Transplant 33, 471–476 (2004). https://doi.org/10.1038/sj.bmt.1704389

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704389

Keywords

This article is cited by

Search

Advanced search

Quick links